The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the bethesda system for reporting thyroid cytopathology using subcategorization and braf mutation results

Cancer Cytopathology

Volumn 122, Issue 5, 2014, Pages 368-376

  Hyeon, Jiyeon ^a   Ahn, Soomin ^a   Shin, Jung Hee ^a   Oh, Young Lyun ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Atypia of undetermined significance; Bethesda system for reporting thyroid cytopathology; BRAF mutation; Fine needle aspiration; Follicular lesion of undetermined significance

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ATYPIA OF UNDETERMINED SIGNIFICANCE; BENIGN TUMOR; BETHESDA SYSTEM FOR REPORTING THYROID CYTOPATHOLOGY; BRAF GENE; CANCER CLASSIFICATION; CANCER RISK; CANCER SURGERY; CONTROLLED STUDY; CYTOPATHOLOGY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FOLLICULAR LESION OF UNDETERMINED SIGNIFICANCE; GENE MUTATION; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; MUTATIONAL ANALYSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT IDENTIFICATION; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID TUMOR; TUMOR VOLUME; ADENOCARCINOMA; BRAF MUTATION; CLASSIFICATION; CLINICAL TRIAL; CYTODIAGNOSIS; FOLLOW UP; GENETICS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PAPILLARY CARCINOMA; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ATYPIA OF UNDETERMINED SIGNIFICANCE; BETHESDA SYSTEM FOR REPORTING THYROID CYTOPATHOLOGY; BRAF MUTATION; FINE NEEDLE ASPIRATION; FOLLICULAR LESION OF UNDETERMINED SIGNIFICANCE;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; AGED, 80 AND OVER; BIOPSY, FINE-NEEDLE; CARCINOMA, PAPILLARY; CYTODIAGNOSIS; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84903903140     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21396     Document Type: Article

References (37)

1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164-2167.
2. Kilfoy BA, Zheng T, Holford TR, et al. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control. 2009;20:525-531.
3. Cho BY, Choi HS, Park YJ, et al. Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades. Thyroid. 2013;23:797-804.
4. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212.
5. VanderLaan PA, Marqusee E, Krane JF. Clinical outcome for atypia of undetermined significance in thyroid fine-needle aspirations: should repeated fna be the preferred initial approach? Am J Clin Pathol. 2011;135:770-775.
6. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
7. Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol. 2008;36:425-437. (Pubitemid 351829800)
8. Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2009;19:1159-1165.
9. Olson MT, Clark DP, Erozan YS, Ali SZ. Spectrum of risk of malignancy in subcategories of 'atypia of undetermined significance'. Acta Cytol. 2011;55:518-525.
10. Horne MJ, Chhieng DC, Theoharis C, et al. Thyroid follicular lesion of undetermined significance: Evaluation of the risk of malignancy using the two-tier sub-classification. Diagn Cytopathol.2012;40:410-415.
11. Ohori NP, Schoedel KE. Variability in the atypia of undetermined significance/follicular lesion of undetermined significance diagnosis in the Bethesda System for Reporting Thyroid Cytopathology: sources and recommendations. Acta Cytol. 2011;55:492-498.
12. Song JY, Chu YC, Kim L, Park IS, Han JY, Kim JM. Reclassifying formerly indeterminate thyroid FNAs using the Bethesda system reduces the number of inconclusive cases. Acta Cytol. 2012;56:122-129.
13. Shi Y, Ding X, Klein M, et al. Thyroid fine-needle aspiration with atypia of undetermined significance: a necessary or optional category? Cancer. 2009;117:298-304.
14. Kocjan G, Chandra A, Cross PA, et al. The interobserver reproducibility of thyroid fine-needle aspiration using the UK Royal College of Pathologists' classification system. Am J Clin Pathol. 2011; 135:852-859.
15. Krane JF, Vanderlaan PA, Faquin WC, Renshaw AA. The atypia of undetermined significance/follicular lesion of undetermined significance: malignant ratio: a proposed performance measure for reporting in The Bethesda System for thyroid cytopathology. Cancer Cytopathol. 2012;120:111-116.
16. Nagarkatti SS, Faquin WC, Lubitz CC, et al. Management of thyroid nodules with atypical cytology on fine-needle aspiration biopsy. Ann Surg Oncol. 2013;20:60-65.
17. Luu MH, Fischer AH, Stockl TJ, Pisharodi L, Owens CL. Atypical follicular cells with equivocal features of papillary thyroid carcinoma is not a low-risk cytologic diagnosis. Acta Cytol. 2011;55:526-530.
18. Moon WJ, Jung SL, Lee JH, et al. Benign and malignant thyroid nodules: US differentiation-multicenter retrospective study. Radiology. 2008;247:762-770.
19. Cibas ES Ali SZ, eds. The Bethesda system for Reporting Thyroid Cytopathology: Definition, Criteria, and Explanatory Notes. New York: Springer; 2009.
20. Bongiovanni M, Krane JF, Cibas ES, Faquin WC. The atypical thyroid fine-needle aspiration: past, present, and future. Cancer Cytopathol. 2012;120:73-86.
21. VanderLaan PA, Marqusee E, Krane JF. Usefulness of diagnostic qualifiers for thyroid fine-needle aspirations with atypia of undetermined significance. Am J Clin Pathol. 2011;136:572-577.
22. Kelman AS, Rathan A, Leibowitz J, Burstein DE, Haber RS. Thyroid cytology and the risk of malignancy in thyroid nodules: importance of nuclear atypia in indeterminate specimens. Thyroid. 2001;11:271-277. (Pubitemid 32298425)
23. Bonzanini M, Amadori P, Morelli L, et al. Subclassification of the "grey zone" of thyroid cytology; a retrospective descriptive study with clinical, cytological, and histological correlation. J Thyroid Res. 2011;2011:251680.
24. Nikiforov YE. Molecular analysis of thyroid tumors. Mod Pathol. 2011;24(Suppl 2):S34-S43.
25. Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367:705-715.
26. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RASBRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454-1457. (Pubitemid 36373628)
27. Nikiforova MN, Nikiforov YE. Molecular diagnostics and predictors in thyroid cancer. Thyroid. 2009;19:1351-1361.
28. Colanta A, Lin O, Tafe L, et al. BRAF mutation analysis of fineneedle aspiration biopsies of papillary thyroid carcinoma: impacton diagnosis and prognosis. Acta Cytol. 2011;55:563-569.
29. Lee ST, Kim SW, Ki CS, et al. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area. J Clin Endocrinol Metab. 2012;97:2299-2306.
30. Ohori NP, Singhal R, Nikiforova MN, et al. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma. Cancer Cytopathol. 2013;121:197-205.
31. Adeniran AJ, Hui P, Chhieng DC, Prasad ML, Schofield K, Theoharis C. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance. Acta Cytol. 2011;55: 570-575.
32. Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathol. 2010;118:17-23.
33. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96:3390-3397.
34. Kang G, Cho EY, Shin JH, Chung JH, Kim JW, Oh YL. Role of BRAFV600E mutation analysis and second cytologic review of fine-needle aspiration for evaluating thyroid nodule. Cancer Cytopathol. 2012;120:44-51.
35. Rossi M, Buratto M, Bruni S, et al. Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study. J Clin Endocrinol Metab. 2012;97:2354-2361.
36. Mekel M, Nucera C, Hodin RA, Parangi S. Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules. Am J Surg. 2010;200:136-143.
37. Kim SK, Hwang TS, Yoo YB, et al. Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab. 2011;96: 658-664.